CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,800,541 | -24.8% | 456,106 | -44.8% | 0.00% | -20.0% |
| Q2 2023 | $9,044,229 | +162.5% | 825,957 | +109.1% | 0.01% | +150.0% |
| Q1 2023 | $3,445,176 | +332.0% | 395,089 | +210.6% | 0.00% | – |
| Q4 2022 | $797,519 | +79.2% | 127,196 | 0.0% | 0.00% | – |
| Q3 2022 | $445,000 | +18.7% | 127,196 | 0.0% | 0.00% | – |
| Q2 2022 | $375,000 | -26.8% | 127,196 | -22.8% | 0.00% | – |
| Q1 2022 | $512,000 | -10.5% | 164,703 | -2.7% | 0.00% | – |
| Q4 2021 | $572,000 | -6.2% | 169,280 | +1.3% | 0.00% | – |
| Q3 2021 | $610,000 | -65.7% | 167,066 | -59.0% | 0.00% | -100.0% |
| Q2 2021 | $1,777,000 | -24.8% | 407,559 | -21.7% | 0.00% | 0.0% |
| Q1 2021 | $2,362,000 | +711.7% | 520,240 | +927.1% | 0.00% | – |
| Q4 2020 | $291,000 | -16.1% | 50,650 | +5.8% | 0.00% | – |
| Q3 2020 | $347,000 | -73.8% | 47,881 | -87.4% | 0.00% | -100.0% |
| Q2 2020 | $1,323,000 | -71.7% | 379,157 | -88.0% | 0.00% | -75.0% |
| Q1 2020 | $4,668,000 | +334.2% | 3,154,427 | +474.1% | 0.00% | +300.0% |
| Q4 2019 | $1,075,000 | -25.5% | 549,419 | +94.8% | 0.00% | 0.0% |
| Q3 2019 | $1,443,000 | +97.7% | 281,991 | +175.9% | 0.00% | – |
| Q2 2019 | $730,000 | -74.1% | 102,217 | -51.8% | 0.00% | -100.0% |
| Q1 2019 | $2,816,000 | +471.2% | 212,182 | +237.9% | 0.00% | – |
| Q4 2018 | $493,000 | -83.6% | 62,794 | -76.9% | 0.00% | -100.0% |
| Q3 2018 | $3,015,000 | -10.3% | 272,312 | +8.7% | 0.00% | 0.0% |
| Q2 2018 | $3,361,000 | +24.1% | 250,528 | +20.2% | 0.00% | 0.0% |
| Q1 2018 | $2,708,000 | +185.4% | 208,495 | +101.9% | 0.00% | 0.0% |
| Q4 2017 | $949,000 | -67.6% | 103,255 | -71.6% | 0.00% | -50.0% |
| Q3 2017 | $2,933,000 | +107.4% | 363,960 | +48.2% | 0.00% | +100.0% |
| Q2 2017 | $1,414,000 | +504.3% | 245,541 | +351.2% | 0.00% | – |
| Q1 2017 | $234,000 | – | 54,419 | +79927.9% | 0.00% | – |
| Q2 2016 | $0 | – | 68 | 0.0% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 68 | -95.6% | 0.00% | – |
| Q4 2015 | $2,000 | 0.0% | 1,562 | +420.7% | 0.00% | – |
| Q4 2014 | $2,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |